A detailed history of Van Eck Associates Corp transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 140,154 shares of TGTX stock, worth $4.44 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
140,154
Holding current value
$4.44 Million
% of portfolio
0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 29, 2025

BUY
$21.31 - $35.09 $2.99 Million - $4.92 Million
140,154 New
140,154 $4.22 Million
Q2 2021

Aug 10, 2021

SELL
$32.5 - $48.96 $1.15 Million - $1.74 Million
-35,483 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$41.61 - $54.3 $1.48 Million - $1.93 Million
35,483 New
35,483 $1.71 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.61B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.